Amicogen, Inc (092040) Fair Value & Analysis
Healthcare · KR · Market cap 73.9B KRW
Fair value as of: Jul 6, 2026
From 3 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 7,700 KRW to 186.78 KRW (−97.6%) since Jun 24, 2026. Share price −9.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,175 KRW – 4,240 KRW · fair‑value band 168.70 KRW – 214.91 KRW · the 1,341 KRW price screens above the 186.78 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Amicogen, Inc (092040) currently trades at 1,341 KRW, while our model-based Fair Value estimate is 186.78 KRW — implying the stock looks roughly 86.1% overvalued today. We read business quality at 22/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Amicogen, Inc generated revenue of 43.4B KRW at a net margin of -10.5%. Revenue grew 13.5% year over year. It earns a return on equity of -4.0%. Net debt stands at 86.8B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 168.70 KRW (bear case) to 214.91 KRW (bull case); at 1,341 KRW, the current price sits above that range. The share trades about 70% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside — at -86%, 092040 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. The company was incorporated in 2000 and is headquartered in Jinju-Si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amicogen, Inc reported revenue of 42.0B KRW in FY2025 versus 125B KRW in FY2021, a compound −23.9%/yr. Reported net income was −30.0B KRW in FY2025.
Is 092040 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹991.46 | -47% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amicogen, Inc (092040) undervalued?
What is the fair value of 092040?
What is the quality score of 092040?
What is the revenue of Amicogen, Inc (092040)?
What is the net profit margin of 092040?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.